Biogen’s Fampyra Is Felled In Canada
Pharmascience And Taro Succeed With Patent Invalidity Challenge
More than a dozen claims in a Canadian patent shielding Biogen’s Fampyra treatment for multiple sclerosis have been cut following challenges launched by two generics firms.
You may also be interested in...
Korean firm Celltrion is aiming to move production of insulin pens inside Korea “for the first time” and break the stranglehold of Big Pharma insulin players in the market by launching a biosimilar product in 2025.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.
Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.